


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31198525</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">2040-2392</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular autism</Title>
                <ISOAbbreviation>Mol Autism</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CYFIP1 overexpression increases fear response in mice but does not affect social or repetitive behavioral phenotypes.</ArticleTitle>
            <Pagination>
                <MedlinePgn>25</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13229-019-0278-0</ELocationID>
            <Abstract>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">CYFIP1, a protein that interacts with FMRP and regulates protein synthesis and actin dynamics, is overexpressed in Dup15q syndrome as well as autism spectrum disorder (ASD). While <i>CYFIP1</i> heterozygosity has been rigorously studied due to its loss in 15q11.2 deletion, Prader-Willi and Angelman syndrome, the effects of <i>CYFIP1</i> overexpression, as is observed in patients with <i>CYFIP1</i> duplication, are less well understood.</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">We developed and validated a mouse model of human <i>CYFIP1</i> overexpression (<i>CYFIP1</i> OE) using qPCR and western blot analysis. We performed a large battery of behavior testing on these mice, including ultrasonic vocalizations, three-chamber social assay, home-cage behavior, Y-maze, elevated plus maze, open field test, Morris water maze, fear conditioning, prepulse inhibition, and the hot plate assay. We also performed RNA sequencing and analysis on the basolateral amygdala.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Extensive behavioral testing in <i>CYFIP1</i> OE mice reveals no changes in the core behaviors related to ASD: social interactions and repetitive behaviors. However, we did observe mild learning deficits and an exaggerated fear response. Using RNA sequencing of the basolateral amygdala, a region associated with fear response, we observed changes in pathways related to cytoskeletal regulation, oligodendrocytes, and myelination. We also identified GABA-A subunit composition changes in basolateral amygdala neurons, which are essential components of the neural fear conditioning circuit.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Overall, this research identifies the behavioral and molecular consequences of <i>CYFIP1</i> overexpression and how they contribute to the variable phenotype seen in Dup15q syndrome and in ASD patients with excess CYFIP1.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fricano-Kugler</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>1Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 USA.</Affiliation>
                        <Identifier Source="ISNI">0000 0000 9632 6718</Identifier>
                        <Identifier Source="GRID">grid.19006.3e</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gordon</LastName>
                    <ForeName>Aaron</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>2Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA.</Affiliation>
                        <Identifier Source="ISNI">0000 0000 9632 6718</Identifier>
                        <Identifier Source="GRID">grid.19006.3e</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shin</LastName>
                    <ForeName>Grace</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>1Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 USA.</Affiliation>
                        <Identifier Source="ISNI">0000 0000 9632 6718</Identifier>
                        <Identifier Source="GRID">grid.19006.3e</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Kun</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>2Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA.</Affiliation>
                        <Identifier Source="ISNI">0000 0000 9632 6718</Identifier>
                        <Identifier Source="GRID">grid.19006.3e</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Jade</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>1Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 USA.</Affiliation>
                        <Identifier Source="ISNI">0000 0000 9632 6718</Identifier>
                        <Identifier Source="GRID">grid.19006.3e</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berg</LastName>
                    <ForeName>Jamee</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>1Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 USA.</Affiliation>
                        <Identifier Source="ISNI">0000 0000 9632 6718</Identifier>
                        <Identifier Source="GRID">grid.19006.3e</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Starks</LastName>
                    <ForeName>Mary</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>2Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA.</Affiliation>
                        <Identifier Source="ISNI">0000 0000 9632 6718</Identifier>
                        <Identifier Source="GRID">grid.19006.3e</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Geschwind</LastName>
                    <ForeName>Daniel H</ForeName>
                    <Initials>DH</Initials>
                    <Identifier Source="ORCID">0000-0003-2896-3450</Identifier>
                    <AffiliationInfo>
                        <Affiliation>3Program in Neurobehavioral Genetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 USA.</Affiliation>
                        <Identifier Source="ISNI">0000 0000 9632 6718</Identifier>
                        <Identifier Source="GRID">grid.19006.3e</Identifier>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>4Center for Autism Research and Treatment, Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 USA.</Affiliation>
                        <Identifier Source="ISNI">0000 0000 9632 6718</Identifier>
                        <Identifier Source="GRID">grid.19006.3e</Identifier>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>5Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 USA.</Affiliation>
                        <Identifier Source="ISNI">0000 0000 9632 6718</Identifier>
                        <Identifier Source="GRID">grid.19006.3e</Identifier>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Mol Autism</MedlineTA>
            <NlmUniqueID>101534222</NlmUniqueID>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Autism spectrum disorder (ASD)</Keyword>
            <Keyword MajorTopicYN="N">CYFIP1</Keyword>
            <Keyword MajorTopicYN="N">Dup15q</Keyword>
            <Keyword MajorTopicYN="N">Fear conditioning</Keyword>
            <Keyword MajorTopicYN="N">Mouse behavior</Keyword>
            <Keyword MajorTopicYN="N">Neurodevelopmental disorders</Keyword>
            <Keyword MajorTopicYN="N">RNA sequencing</Keyword>
        </KeywordList>
        <CoiStatement>Competing interestsThe authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31198525</ArticleId>
            <ArticleId IdType="doi">10.1186/s13229-019-0278-0</ArticleId>
            <ArticleId IdType="pii">278</ArticleId>
            <ArticleId IdType="pmc">PMC6555997</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

